- Moderna and BioNtech surged in trading Thursday amid an update on COVID-19 vaccine development.
- Investor focus on a potential vaccine is increasing as daily cases of COVID-19 spike across the United States and in Europe.
- Moderna said it was “actively preparing for the launch”; of its COVID-19 vaccine, while a report from the Wall Street Journal said Germany could begin vaccinating this year with the vaccine please BioNtech.
- Visit the Business Insider home page for more news.
Moderna and BioNtech surged in trading Thursday as investor focus on the successful COVID-19 vaccine remained high amid rising daily viral infections.
Moderna trades 13% higher, while BioNtech is up 11%.
In its third-quarter earnings report, Moderna said it was “actively preparing for the launch” of its COVID-19 vaccine.
Moderna’s phase III trial of the vaccine candidate has been fully registered with 30,000 patients.
To date, Moderna has received more than $ 1 billion in deposits from governments around the world who wish to successfully distribute COVID-19 vaccine.
The most recent deal Moderna reached was with Japan’s Takeda, announced earlier today. Moderna will provide Takeda with 50 million doses of its COVID-19 vaccine in the first half of 2021 while it awaits approval in Japan.
Depending on the results of a clinical trial, BioNtech’s COVID-19 vaccine could quickly be distributed across Germany by the end of this year, The Wall Street Journal reported on Thursday.
Read more: BANK OF AMERICA: Buy these 6 food warehouses in the best location to celebrate Halloween at home when towns refrain from scams or treats
According to people familiar with the strategy, a plan is in place so that the BioNtech doses will be shipped to more than 60 regional vaccine centers in Germany within hours of approval.
The first people to successfully receive COVID vaccines in Germany will include healthcare workers, the elderly and clinically vulnerable, among others.
BioNtech has partnered with Pfizer to develop the COVID-19 vaccine, and it hopes to submit its vaccine for licensing in November.
BioNtech and Pfizer have already produced millions of doses of their vaccine so they can be shipped on a pre-purchase contract, according to The Wall Street Journal.
Vaccines cannot be born soon. The United States experienced record daily cases of the virus over the weekend and new containment measures hit Germany and France as they tried to stop the virus’s resurgence.
Read more: Here are 6 great tips for trading European stocks after the US election, from investment giants UBS and Barclays.